Trial Profile
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Amivantamab (Primary) ; Lazertinib (Primary) ; Carboplatin; Pemetrexed
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; First in man; Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms CHRYSALIS
- Sponsors Janssen Pharmaceutical KK; Janssen Research & Development
- 05 Dec 2023 Planned End Date changed from 30 Jan 2024 to 31 Dec 2024.
- 07 Nov 2023 Planned End Date changed from 26 Jan 2024 to 30 Jan 2024.
- 07 Nov 2023 Status changed from recruiting to active, no longer recruiting.